Biotech · Private company
Juno Therapeutics, a Subsidiary of Celgene
Track this companyFree. Adds Juno Therapeutics, a Subsidiary of Celgene to your Dealase workspace and tells you when its record changes.
Clinical trials111 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline18
- JCAR015 (CD19-targeted CAR T cells)Phase 2 · Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- JCAR017 (lisocabtagene maraleucel)Phase 2 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- JCAR017 (lisocabtagene maraleucel) + ibrutinibPhase 2 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- JCAR017 (lisocabtagene maraleucel) + venetoclaxPhase 2 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
- JCARH125Phase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- JCARH125 + anakinraPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- lisocabtagene maraleucelPhase 2 · Lymphoma, Non-HodgkinClinicalTrials.gov · fetched Nov 12, 2026
- BendamustinePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- CC-95266Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- CC-97540Phase 1 · Lymphoma Non-HodgkinClinicalTrials.gov · fetched Nov 12, 2026
- CC-98633Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- JCAR017 (lisocabtagene maraleucel) 2-dose schedulePhase 1 · Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- JCAR017 (lisocabtagene maraleucel) single-dose schedulePhase 1 · Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- JCAR015Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- JCAR017Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- JCARH125Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple MyelomaPHASE1 · COMPLETED · started Feb 24, 2021ClinicalTrials.gov NCT04674813 · fetched Nov 12, 2026
- A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple MyelomaPHASE1 · COMPLETED · started Aug 18, 2020ClinicalTrials.gov NCT04394650 · fetched Nov 12, 2026
- A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin LymphomaPHASE1 · COMPLETED · started May 21, 2020ClinicalTrials.gov NCT04231747 · fetched Nov 12, 2026
- A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)PHASE2 · COMPLETED · started Nov 29, 2018ClinicalTrials.gov NCT03744676 · fetched Nov 12, 2026
- Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)PHASE2 · COMPLETED · started Jul 27, 2018ClinicalTrials.gov NCT03483103 · fetched Nov 12, 2026
- Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell ProductTERMINATED · started Feb 19, 2018ClinicalTrials.gov NCT03436771 · fetched Nov 12, 2026
- Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple MyelomaPHASE1_PHASE2 · COMPLETED · started Feb 1, 2018ClinicalTrials.gov NCT03430011 · fetched Nov 12, 2026
- Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 27, 2017ClinicalTrials.gov NCT03331198 · fetched Nov 12, 2026
- Long-Term Follow-up Study for Patients Previously Treated With JCAR015COMPLETED · started Aug 30, 2016ClinicalTrials.gov NCT02813252 · fetched Nov 12, 2026
- Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)PHASE1 · COMPLETED · started Jan 6, 2016ClinicalTrials.gov NCT02631044 · fetched Nov 12, 2026
- Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)PHASE2 · TERMINATED · started Aug 21, 2015ClinicalTrials.gov NCT02535364 · fetched Nov 12, 2026